The Medical Letter on Drugs and Therapeutics
SGLT2 Inhibitors: New Reports
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The recent report of a reduction in cardiovascular mortality in patients with type 2 diabetes treated with the SGLT2 inhibitor empagliflozin (Jardiance) was published soon after the FDA issued new warnings about an increased risk of fractures with canagliflozin (Invokana).

SGLT2 INHIBITORS — SGLT2 (sodium-glucose co-transporter 2), a membrane protein expressed mainly in the kidney, transports filtered glucose from the proximal renal tubule into tubular epithelial cells. SGLT2 inhibitors decrease renal glucose reabsorption and increase urinary glucose excretion, resulting in lower blood glucose levels that are independent of insulin secretion and a modest reduction in HbA1c. These drugs also increase urinary sodium excretion, cause weight loss, and lower blood pressure.

View our detailed online table: SGLT-2 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: SGLT2 Inhibitors: New Reports
Article code: 1479a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian